Vistagen Provides Corporate Update and Reports Fiscal 2024 Second Quarter Financial Results - Vistagen Therapeutics (NASDAQ:VTGN)
Fasedienol (PH94B) PALISADE Phase 3 Program for acute treatment of social anxiety disorder (SAD) advancing to build on recent positive PALISADE-2 Phase 3 results Preparations to initiate potential fasedienol
United States Cindy Anderson Jerrold Dotson Shawn Singh Drug Administration Company Quarterly Report On Form
Source: benzinga.com